BioSpace News Archive

Dental acrylic-based resins are frequently used in day-to-day dentistry practice. The most common use of the dental acrylic includes denture liners and denture bases, orthodontic appliances, and temporary crowns.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to Fact.MR’s analysis, The Demand for Blood Collection Tubes For Liquid Biopsy will expand at an impressive CAGR of around 12% from 2021 to 2031.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global in vitro diagnostic reagents market is expected to be driven by an increase in the number of authorized clinical laboratories and the prevalence of chronic diseases.

The autologous cell therapy market is prognosticated to observe steady growth during the forecast period of 2019-2027.

Age-related macular degeneration is also called macular degeneration, ARMD, or AMD. AMD is a disease of retina that blurs the sharp central vision, which is important for various activities that involve looking straight ahead such as driving, using computer, watching television, sewing, and reading.

Transthyretin amyloidosis is a rare progressive fatal disease that destroys the nerve cells controlling various bodily functions. The symptoms of the disease are similar to those of many other diseases.

Currently, the global market for 3D printed drug is in its budding stage; however, it is poised to undergo a phase of positive growth over the next few years.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., has issued a CEO Update announcing that the U.S. Food and Drug Administration has denied Breakthrough Therapy Designation for aviptadil.

DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the 4th Annual Evercore ISI HealthCONx Conference.

Philogen S.p.A. has entered into a new collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecules of pharmaceutical interest utilizing Philochem’s novel lead-generation technologies.